Organon & Co. (OGN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Organon & Co. (OGN) Healthcare & Pipeline Overview

Organon & Co. delivers health solutions globally, focusing on women's health, biosimilars, and established brands. With a diverse portfolio of prescription therapies, Organon serves drug wholesalers, retailers, hospitals, and government agencies. The company's market position is supported by a 4.0% profit margin and a 0.60% dividend yield.

What Is the Investment Thesis for OGN?

Organon & Co. presents a mixed investment thesis. The company's focus on women's health and biosimilars offers growth potential, particularly given the increasing demand for these products. Organon's established brands provide a stable revenue base, contributing to a profit margin of 4.0%. However, the company faces risks related to competition from other pharmaceutical companies and potential patent expirations. With a market capitalization of $3.61B and a P/E ratio of 18.5, Organon's valuation reflects both its growth prospects and inherent risks. Upcoming catalysts include potential new product launches and expansion into emerging markets. Investors should closely monitor Organon's ability to innovate and maintain its market share.

Based on FMP financials and quantitative analysis

OGN Key Highlights

Market Cap of $3.61B indicates a mid-sized player in the pharmaceutical industry.

• P/E ratio of 18.5 suggests the company is reasonably valued compared to its earnings.
• Profit Margin of 4.0% reflects the company's ability to generate profit from its revenue.
• Gross Margin of 53.1% indicates a strong ability to control the cost of goods sold.
• Dividend Yield of 0.60% provides a small return to investors through dividends.

Who Are OGN's Competitors?

OGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are OGN's Key Strengths?

Diverse product portfolio across multiple therapeutic areas.

• Strong presence in women's health and biosimilars markets.
• Established brands with customer loyalty.
• Global distribution network.

What Are OGN's Weaknesses?

Reliance on established brands may limit growth potential.

• Competition from larger pharmaceutical companies.
• Exposure to patent expirations and generic competition.
• Relatively low profit margin compared to industry leaders.

What Could Drive OGN Stock Higher?

Potential new product launches in the women's health segment.

• Expansion of biosimilars portfolio into new geographic markets.
• Strategic partnerships to enhance distribution and market access.
• Positive clinical trial results for pipeline products.

What Are the Key Risks for OGN?

Financial-distress signal — its Altman Z-Score of 1.25 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Increased competition from generic drug manufacturers.
• Stringent regulatory requirements and pricing pressures.
• Patent litigation and intellectual property disputes.
• Economic downturns affecting healthcare spending.
• Negative clinical trial results for pipeline products.

What Are the Growth Opportunities for OGN?

• Expansion in Women's Health: Organon can capitalize on the growing global focus on women's health by expanding its product offerings and geographic reach in this segment. Organon's existing portfolio, including Nexplanon/Implanon, provides a strong foundation for further growth. Timeline: Ongoing.
• Biosimilars Market Penetration: Organon's biosimilars portfolio presents a significant growth opportunity, as these products offer cost-effective alternatives to branded biologics. Organon's existing biosimilars, such as Brenzys and Renflexis, can be further expanded into new markets. Timeline: Ongoing.
• Emerging Markets Expansion: Organon can drive growth by expanding its presence in emerging markets, where there is increasing demand for affordable healthcare solutions. These markets offer significant opportunities for Organon's established brands and biosimilars. The emerging markets pharmaceutical sector is growing at a faster rate than developed markets. Organon can leverage its existing distribution network and partnerships to penetrate these markets. Timeline: Ongoing.
• Strategic Acquisitions: Organon can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies with complementary products or technologies can enhance Organon's competitive position and drive revenue growth. Potential targets could include companies specializing in women's health, biosimilars, or other therapeutic areas aligned with Organon's strategic focus. Timeline: Ongoing.
• New Product Development: Organon can invest in research and development to develop new products and therapies that address unmet medical needs. Innovation is crucial for maintaining a competitive edge in the pharmaceutical industry. Organon can focus on developing novel therapies in its key therapeutic areas, such as women's health and biosimilars. This includes investing in clinical trials and regulatory approvals for new products. Timeline: Ongoing.

What Are OGN's Competitive Advantages?

• Established Brand Portfolio: Organon has a portfolio of well-known and trusted brands, providing a stable revenue base and customer loyalty.
• Biosimilars Expertise: Organon's expertise in developing and marketing biosimilars gives it a competitive advantage in this growing market.
• Global Distribution Network: Organon has a global distribution network, allowing it to reach customers in diverse markets.
• Focus on Women's Health: Organon's focus on women's health positions it to capitalize on the increasing demand for these products.

What Does OGN Do?

Organon & Co. was incorporated in 2020 and is headquartered in Jersey City, New Jersey. The company develops and delivers a range of health solutions through its portfolio of prescription therapies, operating both in the United States and internationally. Organon's primary focus areas include women's health, biosimilars, and established brands across various therapeutic areas. Its women's health portfolio features contraception and fertility products, including Nexplanon/Implanon, a long-acting reversible contraceptive. The biosimilars portfolio includes immunology products like Brenzys, Renflexis, and Hadlima, as well as oncology products such as Ontruzant and Aybintio. Organon also provides cardiovascular products, including cholesterol-modifying medicines under brands like Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor, and hypertension treatments like Cozaar and Hyzaar. Additionally, the company offers respiratory products like Singulair, Dulera, Zenhale, and Asmanex for asthma, and Singulair, Nasonex, Clarinex, and Aerius for allergic rhinitis. Organon's portfolio also includes dermatology, bone health, and non-opioid pain management products. The company distributes its products to drug wholesalers, retailers, hospitals, government agencies, and managed health care providers.

What Products and Services Does OGN Offer?

• Develops and delivers prescription therapies globally.
• Focuses on women's health products, including contraception and fertility treatments.
• Offers biosimilars for immunology and oncology.
• Provides cardiovascular products for cholesterol management and hypertension.
• Markets respiratory products for asthma and allergic rhinitis.
• Sells dermatology and bone health products.
• Offers non-opioid pain management solutions.
• Provides treatments for benign prostatic hyperplasia and male pattern hair loss.

How Does OGN Make Money?

• Develops and manufactures prescription drugs.
• Markets and sells products through wholesalers, retailers, hospitals, and government agencies.
• Generates revenue from sales of branded and generic pharmaceuticals.
• Focuses on women's health, biosimilars, and established brands.

What Industry Does OGN Operate In?

Organon & Co. operates in the drug manufacturing industry, which is characterized by intense competition, stringent regulations, and high research and development costs. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. Organon's focus on women's health and biosimilars positions it to capitalize on specific growth areas within the industry. The company competes with both large pharmaceutical companies and smaller, specialized players.

Who Are OGN's Key Customers?

• Drug wholesalers and retailers.
• Hospitals and government agencies.
• Managed health care providers, including HMOs and PBMs.
• Patients who use prescription therapies.

Company Profile

Organon & Co. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Jersey City, US. The company is led by CEO Joseph T. Morrissey Jr.. OGN has traded publicly since 2021.

Organon & Co. Financial Trajectory

Organon & Co. (OGN) reported $1.56B in revenue for Q2 2026, reflecting 6.7% growth compared to the prior quarter. The company recorded net income of $108.0M, with diluted EPS of $0.40. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, OGN averaged $0.19 in diluted EPS.

How Organon & Co. Is Valued

Organon & Co. carries a market capitalization of $3.61B, placing it in the mid-cap category. Relative to its peer group, OGN's quantitative score of 35/100 is below the peer average of 64/100.

Return on equity for Organon & Co. stands at 29.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.9%, showing how much profit it generates from its asset base. OGN trades at a trailing price-to-earnings ratio of 18.55, below the Healthcare sector average of ~23x. Its free cash flow yield is 17.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.97 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.0%, the inverse of the P/E and a quick read on earnings relative to price.

Organon & Co.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.25 places it in the distress zone, a signal of elevated financial risk.

Organon & Co. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 7.4% below estimates on average.

Wall Street analysts project Organon & Co. revenue of about $6.12B for fiscal 2026, with EPS near $3.40. The estimate reflects 4 contributing analysts.

OGN Financials

OGN Latest News

OGN Analyst Consensus

OGN MoonshotScore

Latest Organon & Co. Analysis

Common Questions About OGN (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources